APR-1051
Advanced or Metastatic Solid Tumors (with CCNE1, CCNE2, FBXW7, PPP2R1A, HPV+, or KRAS G12/13 & TP53 mutations)
Key Facts
About Aprea Therapeutics
Aprea Therapeutics is a precision oncology company headquartered in Doylestown, Pennsylvania, focused on developing novel therapeutics that target the DNA Damage Response (DDR) pathways cancer cells rely on for survival. Its core strategy leverages synthetic lethality, aiming to selectively kill cancer cells with specific genetic mutations while sparing healthy tissue. The company's two lead clinical-stage assets, APR-1051 and ATRN-119, are in Phase 1 trials for biomarker-defined advanced solid tumors, with key data readouts anticipated in 2026. Aprea's approach is built on foundational research from its scientific team, positioning it as a player in the competitive but high-potential DDR inhibitor space.
View full company profile